BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31926324)

  • 21. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
    Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ
    Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms.
    Xu JZ; Wang WQ; Zhang SR; Xu HX; Wu CT; Qi ZH; Gao HL; Ni QX; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Mar; 25(3):647-654. PubMed ID: 29235006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
    Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
    Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
    Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
    Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
    Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of lymph node metastasis in pancreatic neuroendocrine tumor.
    Taki K; Hashimoto D; Nakagawa S; Ozaki N; Tomiyasu S; Ohmuraya M; Arima K; Kaida T; Higashi T; Sakamoto K; Sakata K; Okabe H; Nitta H; Hayashi H; Chikamoto A; Beppu T; Takamori H; Hirota M; Baba H
    Surg Today; 2017 Sep; 47(9):1104-1110. PubMed ID: 28229300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
    Zhou B; Zhan C; Xiang J; Ding Y; Yan S
    BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
    Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
    HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pagano N; Santini D; De Giorgio R; Ingaldi C; Tomassetti P; Zani E; Minni F
    Pancreatology; 2016; 16(3):403-10. PubMed ID: 26924664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
    Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
    J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours.
    Feretis M; Wang T; Ghorani E; Balakrishnan A; Harper SJ; Jah A; Huguet EL; Praseedom RK; Liau SS
    Pancreatology; 2019 Oct; 19(7):1000-1007. PubMed ID: 31445889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence.
    Valente R; Lykoudis P; Tamburrino D; Inama M; Passas I; Toumpanakis C; Luong TV; Davidson B; Imber C; Malagò M; Rahman SH; Shankar A; Sharma D; Caplin M; Fusai G
    Eur J Surg Oncol; 2017 Nov; 43(11):2119-2128. PubMed ID: 28821361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
    Zhou B; Fang B; Yan S; Wang W
    Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the new classification of neuroendocrine pancreatic tumors of clinical help?
    Schindl M; Kaczirek K; Kaserer K; Niederle B
    World J Surg; 2000 Nov; 24(11):1312-8. PubMed ID: 11038199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.